Abstract

Abstract:

Abstract

Objective: To analyse long term outcome of pedicled patellar implantation in treating the defect of the knee joint after the excision of giant cell tumor of distal femur.

Methods: The geometry of patella has lead to its use for condylar reconstruction following resection for giant cell tumour around knee. 15 such patients were treated at our institute and followed up for a mean period of 7.3 years. Average age at presentation was 14.8 years. All patients had plain x-rays, angiography as needed, CT scan and MRI to check integrity of articular cartilage and ACL. Size of lesion was measured on CT. Predominant lateral condyle involvement was found in 6 and medial in 9 patients. The patella was dissociated with a slip of quadriceps attached to its proximal superior-medial pole and rotated to place it horizontally in the zone of resection. Firm osteosynthesis to intact condyle and autogenous bone grafting was carried out.

Results: Grafts consolidated at a mean of 10.8 months. All joints were fairly stable and 70% had movement of 90 degrees without pain. 11 patients had excellent outcome with ability to carry on occupations involving manual labour. There were reoperations for 2 deep infections, 1 recurrence leading to arthrodesis, 1 supracondylar fracture, 2 arthrolysis and 1 valgus osteotomy. 4 patients had arthritic changes and extensor leg at 6 years follow up. No AVN changes or extensor mechanism problems occurred. Using chi square test for log rank analysis significant relationship was found between size of lesion and range of motion (P=0.03) as well as articular cartilage grading and development of arthrosis. The rate of healing was faster than other series reporting free patella grafting.

Conclusion: Patellar implantation is a suitable way to repair the defect of the knee with better immediate functional results subsequently delaying eventual prosthesis surgery.

Introduction: To report the results of quadrupled hamstring tendon autograft anterior cruciate ligament reconstruction with bioabsorbable Rigidfix fixation for both femoral and tibial tunnels.

Methods: ninety one patients were retrospectively identified by notes review as having undergone quadrupled hamstring tendon auto graft anterior cruciate ligament reconstruction with Bioabsorbable Rigidfix fixation with a minimum 1 year follow-up[range12 to 34 months] To our knowledge there has been no published results with Rigidfix device used as a method of fixation at both femoral and tibial tunnels

Results: Data were collected on 91 knees in 91 patients (100 %) at an average 13 months (range, 12 to 34) after surgery. They were all asked to fill in a subjective quetionaire. Seventy eight patients returned for clinical evaluation (85.7 % return) and subjective questionnaire was comleted by 78 patients (85.7 %).

The KT-2000 Arthrometer, mean side-to-side difference for manual maximum displacement was 1 mm (range, 0 to 3). Anterior compliance index mean side-to-side difference was1 (range −1 to 3), Quadriceps active displacement tests mean side-to-side difference was.5 [range −1 to 2]. The mean International Knee Documentation Committee knee score was 89 (range, 33.3 to 100).

Conclusions: Quadrupled hamstring tendon auto graft anterior cruciate ligament reconstruction with Bioabsorbable Rigidfix fixation is comparable with other methods of anterior cruciate ligament reconstruction in terms of patient satisfaction, knee stability, and function.

Introduction: Thromboembolic complications are common in both elective and trauma orthopaedic practice. Despite the many studies reported in the literature, there remain a number of unanswered questions regarding the use of thrombophylaxis. The aim of this study was to establish the current practice amongst Irish consultant orthopaedic surgeons regarding thromboprophylaxis.

Materials and Methods: A detailed confidential written questionaire was sent to all consultant orthopaedic surgeons in the republic of Ireland. Surgeons were asked to indicate the type of mechanical and chemothromboprophylaxis in the setting of total hip arthroplasty, knee arthroplasty and hip fracture. They were also questioned regarding 1) time of commencement of therapy 2) duration of therapy 3) method of diagnosis of DVT 4) Estimated incidence of mortality from pulmonary embolism in the last five years 5) Whether there was established protocol for DVT prophylaxis in their unit. 6) Reason for not using chemothromboprophylaxis if not used and 7) whether their method of treatment was influenced by anaesthetic concerns.

Results: The response rate was seventy percent. Over ninetyfive percent of surgeons used a combination of physical and chemical modalities. There was a wide variation between type of therapy, commencement time and duration of prophylaxis. There was a higher rate of intervention and duration of therapy in elective practice. A unit policy regarding thromboprophylaxis existed in a majority of hospitals (54.7%). Forty-seven per cent of respondents felt that there had been no post-operative mortality in their practice in the previous five years from pulmonary embolism. Twenty-six percent of respondents felt that anaesthetists influenced the type of prophylaxis used. The results of this survey shows that venous thromboembolism is regarded as a significant complication of orthopaedic surgery and that most orthopaedic surgeons take active steps to try and prevent its occurrence. There was a higher rate of intervention in this groug of surgeons compared to previous surveys of British orthopaedic surgeons. This may reflect a higher standard of care or a concern regarding the high rate of litigation in the republic of Ireland. However there is no consensus as to the optimum therapy which reflects the conflicting evidence available in the many publications on this subject.

Dupuytren’s disease is a benign fibroproliferative disease of unknown aetiology. It is often familial and commonly affects Northern European Caucasian men, but genetic studies have yet to identify the relevant genes.

Transforming growth factor beta one (TGF-β1) is a multifunctional cytokine which plays a central role in wound healing and fibrosis. It stimulates the proliferation of fibroblasts and the deposition of extracellular matrix. Previous studies have implicated TGF-β1 in Dupuytren’s disease, suggesting that it may represent a candidate susceptibility gene for this condition.

We have investigated the association of four common single nucleotide polymorphisms in TGF-β1 with the risk of developing Dupuytren’s disease. A polymerase chain reaction-restriction fragment length polymorphism method was used for genotyping TGF-β1 polymorphisms. DNA samples from 135 patients with Dupuytren’s disease and 200 control subjects were examined.

There was no statistically significant difference in TGF-β1 genotype or allele frequency distributions between the patients and controls for the codons 10, 25, −509 and −800 polymorphisms.

Our observations suggest that common TGF-β1 polymorphisms are not associated with a risk of developing Dupuytren’s disease. These data should be interpreted with caution since the lack of association was shown in only one series of patients with only known, common polymorphisms of TGF-β1. To our knowledge, this is the first report of a case-control association study in Dupuytren’s disease using single nucleotide polymorphisms in TGF-β1.